Mr. Philip Ferneau is a Co-Founder and serves as Managing Partner at Borealis Ventures. He served as Board Member at Avitide. He also serves as Board Member & Investor at Compass Therapeutics and Board Member at Amagma Therapeutics, Ovation, and Vets First Choice. He capitalizes on over fifteen years of experience working with entrepreneurs in the extended Dartmouth College network and other centers of innovation to identify and support the most promising technology commercialization opportunities. He currently is a Director on the boards of Borealis portfolio companies PCD Partners and Direct Vet Marketing. and served on the board of Avedro. He also led Borealis' investment in Adimab and the firm's prior investments in Medical Metrx Solutions (acquired by AIG Altaris Health Partners) and GlycoFi (acquired by Merck & Company). He joined Borealis from Dartmouth College's Tuck School of Business, where he was the founding Executive Director of the Center for Private Equity and Entrepreneurship and an adjunct professor teaching venture capital and entrepreneurship topics. He remains a Fellow at the Center and teaches an advanced venture capital seminar each year. He is also a Fellow of the Dartmouth Entrepreneurial Network and a board director of the Dartmouth Regional Technology Center. Prior to joining the Tuck faculty, He held senior strategy and business development roles at a privately-held application software company in New Hampshire. Earlier in private legal practice, he counseled technology startups, Fortune 500 companies, and foreign governments on sensitive trade, tax, and investment matters. He received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law, and an M.B.A. from the Tuck School of Business at Dartmouth (with High Distinction). A Tuck Scholar, He also received the Tuck School's Adams Award for Entrepreneurship and the Walter Jacobs Prize for Intellectual Leadership. He serves as Board Member at T-Cypher Bio.